HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.

AbstractPURPOSE:
Non-vitamin K antagonist oral anticoagulant medications are increasingly used for stroke prophylaxis in patients with nonvalvular atrial fibrillation (NVAF). This study aimed to compare adherence with rivaroxaban and apixaban among patients with NVAF in routine clinical practice.
METHODS:
Using pharmacy and medical claims from Truven Health Analytics MarketScan databases, we identified NVAF patients aged ≥18 years treated with rivaroxaban or apixaban. Baseline demographic and clinical features were balanced using 1:1 propensity score matching. Adherence to therapy was measured at 90 and 180 days post-index date and was defined by the proportion of days covered (PDC) ≥0.80 and PDC ≥0.90. "Gaps in care," defined as those with 10 or more day gaps in supply, were also evaluated.
FINDINGS:
Between June 2012 and April 2014, 11,477 rivaroxaban and 2992 apixaban users were identified. Baseline characteristics for rivaroxaban and apixaban users were well matched. Relative to apixaban users, rivaroxaban users were more likely to have a PDC ≥0.80 at both 90 days (85.3% vs 79.9%; P < 0.001) and 180 days (75.8% vs 72.2%; P = 0.001). Similar results were observed with PDC ≥0.90. The proportion of patients with at least one 5+ and 10+ day gap in prescriptions was significantly lower in the rivaroxaban versus apixaban cohorts: 54.2% versus 62.4% (P < 0.001) and 40.0% versus 49.2% (P < 0.001), respectively.
IMPLICATIONS:
Adherence to non-vitamin K antagonist oral anticoagulants among NVAF patients is less than ideal, and gaps in treatment are common. Those on once-a-day rivaroxaban had significantly higher adherence and fewer gaps in treatment compared with twice-a-day apixaban. Future studies are needed to explore whether these treatment differences affect comparative patient outcomes.
AuthorsColleen A McHorney, Eric D Peterson, François Laliberté, Guillaume Germain, Winnie W Nelson, Concetta Crivera, Jeffrey Schein, Patrick Lefebvre
JournalClinical therapeutics (Clin Ther) Vol. 38 Issue 11 Pg. 2477-2488 (Nov 2016) ISSN: 1879-114X [Electronic] United States
PMID27789043 (Publication Type: Comparative Study, Journal Article)
CopyrightCopyright © 2016 Elsevier HS Journals, Inc. All rights reserved.
Chemical References
  • Anticoagulants
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban
Topics
  • Aged
  • Aged, 80 and over
  • Anticoagulants (administration & dosage, therapeutic use)
  • Atrial Fibrillation (drug therapy)
  • Databases, Factual
  • Female
  • Humans
  • Male
  • Medication Adherence
  • Middle Aged
  • Propensity Score
  • Pyrazoles (administration & dosage)
  • Pyridones (administration & dosage)
  • Rivaroxaban (administration & dosage)
  • Stroke (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: